Skip to main content
Top

Drugs & Aging

1997 - 2023
Volumes
333
Issues
Chevron right icon
Issue 10/2023
Latest issue

About this journal

For 30 years Drugs & Aging has been delivering essential information on the most important aspects of drug therapy to researchers and healthcare professionals involved in the care of older patients.

Through a program of reviews and original research articles, the journal addresses major issues relating to drug therapy in older adults, including the management of specific diseases or disorders, particularly those associated with aging, age-related physiological changes impacting drug therapy, and issues related to drug utilization and prescribing.

As a hybrid journal, Drugs & Aging does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.

Drugs & Aging offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Metadata
Title
Drugs & Aging
Coverage
Volume 10/1997 - Volume 40/2023
Publisher
Springer International Publishing
Electronic ISSN
1179-1969
Print ISSN
1170-229X
Journal ID
40266
DOI
https://doi.org/10.1007/40266.1179-1969

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

A 28-year-old male patient (188 cm, 72 kg) presents to the central emergency department with dorsal pain after returning from a trip to East Asia. He reports feeling a bit tired and listless without classic signs of infection. In the clinical examination, apart from an approximately fist-sized, deeply situated, sturdy and non-displaceable bulging of the abdominal wall sinistrally paraumbilically, a slight enlargement of the left testis with pain upon palpation is noticeable. What is your first suspicion, and what are your first diagnostic steps?

The 46-year-old male patient has been showing various signs of inflammation for 6–8 weeks: Sore throat, canker sores, joint pain and febrile rhinitis. There is an unintended weight loss of 2–3 kg. Physical examination reveals findings that are inconspicuous for the patient’s age. How do you proceed now?

A 76-year-old, overweight female patient with anaemia and type II diabetes noted by her family doctor presents with fatigue, forgetfulness and yellowish pallor in a neglected state. Moreover, she shows an increasingly unsteady gait. How do you proceed?

A 56-year-old man presents with concentration problems, dorsal pain, fatigue and a marked increase in urination. His family history is positive for bronchial carcinoma. Physical examination reveals tenderness upon percussion in the lumbar spine. How do you proceed?

Navigating the Treatment of Renal Cell Carcinoma

Insights on the Current Treatment Landscape and Managing Patient Health

In recent years, tremendous efforts have been made in the medical treatment of metastatic renal cell carcinoma (mRCC), with Immune-Oncological combinations standing as the current standard of care in the first-line setting of mRCC. 

In these podcasts, expert authors discuss the current treatment landscape for these new therapies and discuss what should be taken into account when choosing the most appropriate treatment for their patients so as to balance oncological outcomes, adverse events and quality of life.

Supported by an unrestricted educational grant from Eisai Europe Limited.

Listen now